Los Angeles Capital Management & Equity Research Inc. Buys Shares of 12,550 Eagle Pharmaceuticals Inc (EGRX)

Los Angeles Capital Management & Equity Research Inc. bought a new position in Eagle Pharmaceuticals Inc (NASDAQ:EGRX) during the third quarter, HoldingsChannel reports. The institutional investor bought 12,550 shares of the specialty pharmaceutical company’s stock, valued at approximately $870,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. BlackRock Inc. increased its stake in Eagle Pharmaceuticals by 14.7% in the 2nd quarter. BlackRock Inc. now owns 1,432,090 shares of the specialty pharmaceutical company’s stock worth $108,351,000 after acquiring an additional 183,287 shares during the last quarter. Rothschild Asset Management Inc. bought a new position in Eagle Pharmaceuticals in the 2nd quarter worth about $30,835,000. Granite Investment Partners LLC increased its stake in Eagle Pharmaceuticals by 74.0% in the 2nd quarter. Granite Investment Partners LLC now owns 198,774 shares of the specialty pharmaceutical company’s stock worth $15,039,000 after acquiring an additional 84,567 shares during the last quarter. Northern Trust Corp increased its stake in Eagle Pharmaceuticals by 23.0% in the 2nd quarter. Northern Trust Corp now owns 164,571 shares of the specialty pharmaceutical company’s stock worth $12,452,000 after acquiring an additional 30,773 shares during the last quarter. Finally, Chartwell Investment Partners LLC bought a new position in Eagle Pharmaceuticals in the 2nd quarter worth about $12,063,000.

EGRX opened at $48.48 on Friday. Eagle Pharmaceuticals Inc has a 12-month low of $46.88 and a 12-month high of $85.66. The company has a debt-to-equity ratio of 0.20, a current ratio of 5.59 and a quick ratio of 5.38. The stock has a market capitalization of $726.12 million, a PE ratio of 23.30 and a beta of 1.72.

Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its quarterly earnings data on Thursday, November 1st. The specialty pharmaceutical company reported $1.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.91 by $0.27. Eagle Pharmaceuticals had a return on equity of 17.62% and a net margin of 13.92%. The firm had revenue of $51.34 million during the quarter, compared to analysts’ expectations of $52.70 million. During the same period in the prior year, the business earned $1.22 EPS. The company’s revenue for the quarter was down 18.5% compared to the same quarter last year. As a group, equities research analysts expect that Eagle Pharmaceuticals Inc will post 2.03 EPS for the current year.

A number of research firms have recently issued reports on EGRX. Zacks Investment Research upgraded Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 9th. BidaskClub upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, September 29th. TheStreet upgraded Eagle Pharmaceuticals from a “c” rating to a “b-” rating in a report on Thursday, August 9th. Cantor Fitzgerald cut Eagle Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Thursday, November 1st. Finally, Piper Jaffray Companies set a $88.00 price objective on Eagle Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 7th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the stock. Eagle Pharmaceuticals presently has an average rating of “Hold” and an average target price of $77.17.

TRADEMARK VIOLATION WARNING: This news story was originally posted by WKRB News and is the property of of WKRB News. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.wkrb13.com/2018/11/24/los-angeles-capital-management-equity-research-inc-buys-shares-of-12550-eagle-pharmaceuticals-inc-egrx.html.

Eagle Pharmaceuticals Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Further Reading: How does a reverse stock split work?

Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals Inc (NASDAQ:EGRX).

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply